CN104530014B - 2‑氧代‑1,2‑二氢苯并[cd]吲哚‑6‑磺酰胺类化合物及其组合物和应用 - Google Patents
2‑氧代‑1,2‑二氢苯并[cd]吲哚‑6‑磺酰胺类化合物及其组合物和应用 Download PDFInfo
- Publication number
- CN104530014B CN104530014B CN201410821535.5A CN201410821535A CN104530014B CN 104530014 B CN104530014 B CN 104530014B CN 201410821535 A CN201410821535 A CN 201410821535A CN 104530014 B CN104530014 B CN 104530014B
- Authority
- CN
- China
- Prior art keywords
- indoles
- oxo
- ethyl
- dihydrobenzos
- sulfonamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- -1 Sulfamide compound Chemical class 0.000 title claims abstract description 53
- 150000002475 indoles Chemical class 0.000 title claims description 162
- 150000001875 compounds Chemical class 0.000 claims abstract description 72
- 150000003839 salts Chemical class 0.000 claims abstract description 39
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 15
- 201000010099 disease Diseases 0.000 claims abstract description 13
- 239000003814 drug Substances 0.000 claims abstract description 13
- 239000003112 inhibitor Substances 0.000 claims abstract description 10
- 230000004048 modification Effects 0.000 claims abstract description 10
- 238000012986 modification Methods 0.000 claims abstract description 10
- 229940124530 sulfonamide Drugs 0.000 claims description 123
- 238000006467 substitution reaction Methods 0.000 claims description 53
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 40
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 22
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 21
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 18
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 17
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 15
- FKRCODPIKNYEAC-UHFFFAOYSA-N ethyl propionate Chemical compound CCOC(=O)CC FKRCODPIKNYEAC-UHFFFAOYSA-N 0.000 claims description 14
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 11
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 10
- 239000002253 acid Substances 0.000 claims description 9
- 150000001408 amides Chemical class 0.000 claims description 9
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims description 8
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 8
- 125000002757 morpholinyl group Chemical group 0.000 claims description 8
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 8
- 239000005711 Benzoic acid Substances 0.000 claims description 7
- 235000010233 benzoic acid Nutrition 0.000 claims description 7
- JBDSSBMEKXHSJF-UHFFFAOYSA-N cyclopentanecarboxylic acid Chemical compound OC(=O)C1CCCC1 JBDSSBMEKXHSJF-UHFFFAOYSA-N 0.000 claims description 7
- HNAGHMKIPMKKBB-UHFFFAOYSA-N 1-benzylpyrrolidine-3-carboxamide Chemical compound C1C(C(=O)N)CCN1CC1=CC=CC=C1 HNAGHMKIPMKKBB-UHFFFAOYSA-N 0.000 claims description 6
- 125000005605 benzo group Chemical group 0.000 claims description 6
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 claims description 6
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims description 6
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 6
- 241000255964 Pieridae Species 0.000 claims description 5
- 201000004681 Psoriasis Diseases 0.000 claims description 5
- 208000006673 asthma Diseases 0.000 claims description 5
- 150000002148 esters Chemical class 0.000 claims description 5
- 150000002240 furans Chemical class 0.000 claims description 5
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 claims description 5
- QERYCTSHXKAMIS-UHFFFAOYSA-N thiophene-2-carboxylic acid Chemical compound OC(=O)C1=CC=CS1 QERYCTSHXKAMIS-UHFFFAOYSA-N 0.000 claims description 5
- JXOVTPNBOKLRHT-UHFFFAOYSA-N 3,5-dimethyl-4,5-dihydro-1,2-oxazole Chemical class CC1CC(C)=NO1 JXOVTPNBOKLRHT-UHFFFAOYSA-N 0.000 claims description 4
- 208000009386 Experimental Arthritis Diseases 0.000 claims description 4
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 claims description 4
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 claims description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 4
- OBNCKNCVKJNDBV-UHFFFAOYSA-N butanoic acid ethyl ester Natural products CCCC(=O)OCC OBNCKNCVKJNDBV-UHFFFAOYSA-N 0.000 claims description 4
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical group C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims description 4
- 201000002491 encephalomyelitis Diseases 0.000 claims description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 4
- 201000006417 multiple sclerosis Diseases 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 150000003053 piperidines Chemical class 0.000 claims description 4
- 235000019260 propionic acid Nutrition 0.000 claims description 4
- 201000003068 rheumatic fever Diseases 0.000 claims description 4
- VQKFNUFAXTZWDK-UHFFFAOYSA-N 2-Methylfuran Chemical compound CC1=CC=CO1 VQKFNUFAXTZWDK-UHFFFAOYSA-N 0.000 claims description 3
- 125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
- UTCMYCAFVUUNBK-UHFFFAOYSA-N benzo[cd]indole Chemical class C1=CC(C=N2)=C3C2=CC=CC3=C1 UTCMYCAFVUUNBK-UHFFFAOYSA-N 0.000 claims description 3
- PNZXMIKHJXIPEK-UHFFFAOYSA-N cyclohexanecarboxamide Chemical compound NC(=O)C1CCCCC1 PNZXMIKHJXIPEK-UHFFFAOYSA-N 0.000 claims description 3
- ISXSCDLOGDJUNJ-UHFFFAOYSA-N tert-butyl prop-2-enoate Chemical group CC(C)(C)OC(=O)C=C ISXSCDLOGDJUNJ-UHFFFAOYSA-N 0.000 claims description 3
- UEMGWPRHOOEKTA-UHFFFAOYSA-N 1,3-difluorobenzene Chemical compound FC1=CC=CC(F)=C1 UEMGWPRHOOEKTA-UHFFFAOYSA-N 0.000 claims description 2
- OHGRDCDSBYWPEL-UHFFFAOYSA-N 1-fluoroindole Chemical class C1=CC=C2N(F)C=CC2=C1 OHGRDCDSBYWPEL-UHFFFAOYSA-N 0.000 claims description 2
- FZMXBWXWQILZPU-UHFFFAOYSA-N 1-methyl-5-(trifluoromethyl)benzimidazole Chemical class FC(F)(F)C1=CC=C2N(C)C=NC2=C1 FZMXBWXWQILZPU-UHFFFAOYSA-N 0.000 claims description 2
- SIJBDWPVNAYVGY-UHFFFAOYSA-N 2,2-dimethyl-1,3-dioxolane Chemical class CC1(C)OCCO1 SIJBDWPVNAYVGY-UHFFFAOYSA-N 0.000 claims description 2
- 125000006282 2-chlorobenzyl group Chemical group [H]C1=C([H])C(Cl)=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- 125000006179 2-methyl benzyl group Chemical group [H]C1=C([H])C(=C(C([H])=C1[H])C([H])([H])*)C([H])([H])[H] 0.000 claims description 2
- 125000006180 3-methyl benzyl group Chemical group [H]C1=C([H])C(=C([H])C(=C1[H])C([H])([H])[H])C([H])([H])* 0.000 claims description 2
- PTORRJRYAPMYHC-UHFFFAOYSA-N 3-propan-2-yl-4,5-dihydro-1,2-oxazole Chemical class CC(C)C1=NOCC1 PTORRJRYAPMYHC-UHFFFAOYSA-N 0.000 claims description 2
- 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 claims description 2
- 125000006181 4-methyl benzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])C([H])([H])* 0.000 claims description 2
- PMZBHPUNQNKBOA-UHFFFAOYSA-N 5-methylbenzene-1,3-dicarboxylic acid Chemical compound CC1=CC(C(O)=O)=CC(C(O)=O)=C1 PMZBHPUNQNKBOA-UHFFFAOYSA-N 0.000 claims description 2
- UUCUQJHYUPXDHN-UHFFFAOYSA-N N-Acetylindole Chemical compound C1=CC=C2N(C(=O)C)C=CC2=C1 UUCUQJHYUPXDHN-UHFFFAOYSA-N 0.000 claims description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 2
- 229910021529 ammonia Inorganic materials 0.000 claims description 2
- 235000010290 biphenyl Nutrition 0.000 claims description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 235000019253 formic acid Nutrition 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 claims description 2
- 229940095102 methyl benzoate Drugs 0.000 claims description 2
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 2
- 150000003235 pyrrolidines Chemical class 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims 1
- KXDHJXZQYSOELW-UHFFFAOYSA-N carbonic acid monoamide Natural products NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 claims 1
- KJAMZCVTJDTESW-UHFFFAOYSA-N tiracizine Chemical compound C1CC2=CC=CC=C2N(C(=O)CN(C)C)C2=CC(NC(=O)OCC)=CC=C21 KJAMZCVTJDTESW-UHFFFAOYSA-N 0.000 claims 1
- 238000002288 cocrystallisation Methods 0.000 abstract description 5
- 239000012453 solvate Substances 0.000 abstract description 5
- 206010028980 Neoplasm Diseases 0.000 abstract description 4
- 201000011510 cancer Diseases 0.000 abstract description 4
- 239000000651 prodrug Substances 0.000 abstract description 4
- 229940002612 prodrug Drugs 0.000 abstract description 4
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 abstract description 3
- 230000001900 immune effect Effects 0.000 abstract description 3
- 229930002330 retinoic acid Natural products 0.000 abstract description 3
- 208000026278 immune system disease Diseases 0.000 abstract description 2
- 108090000629 orphan nuclear receptors Proteins 0.000 abstract description 2
- 102000004164 orphan nuclear receptors Human genes 0.000 abstract description 2
- 230000001105 regulatory effect Effects 0.000 abstract description 2
- 229940088592 immunologic factor Drugs 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 91
- 238000010189 synthetic method Methods 0.000 description 89
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N DMSO Substances CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 84
- 102000005962 receptors Human genes 0.000 description 51
- 108020003175 receptors Proteins 0.000 description 51
- 239000002585 base Substances 0.000 description 36
- 235000002639 sodium chloride Nutrition 0.000 description 33
- 238000006243 chemical reaction Methods 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 14
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 14
- 230000002401 inhibitory effect Effects 0.000 description 14
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 12
- 239000007787 solid Substances 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 125000001424 substituent group Chemical group 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 239000000370 acceptor Substances 0.000 description 7
- 125000000217 alkyl group Chemical group 0.000 description 7
- 125000000753 cycloalkyl group Chemical group 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 239000003513 alkali Substances 0.000 description 6
- 125000004432 carbon atom Chemical group C* 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 238000004440 column chromatography Methods 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- 102000013691 Interleukin-17 Human genes 0.000 description 5
- 108050003558 Interleukin-17 Proteins 0.000 description 5
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 229910052736 halogen Inorganic materials 0.000 description 5
- 150000002367 halogens Chemical class 0.000 description 5
- 239000012044 organic layer Substances 0.000 description 5
- 125000005936 piperidyl group Chemical group 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 4
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 4
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 4
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 4
- 108700008625 Reporter Genes Proteins 0.000 description 4
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 4
- 239000008365 aqueous carrier Substances 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 4
- 229910052794 bromium Inorganic materials 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 239000000460 chlorine Substances 0.000 description 4
- 229910052801 chlorine Inorganic materials 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 229910052731 fluorine Inorganic materials 0.000 description 4
- 239000011737 fluorine Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 230000003000 nontoxic effect Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- KVHKWAZUPPBMLL-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoro-2-[3-fluoro-4-[4-[[4-(pyridin-4-ylmethyl)piperazin-1-yl]methyl]phenyl]phenyl]propan-2-ol Chemical compound FC1=CC(C(O)(C(F)(F)F)C(F)(F)F)=CC=C1C(C=C1)=CC=C1CN1CCN(CC=2C=CN=CC=2)CC1 KVHKWAZUPPBMLL-UHFFFAOYSA-N 0.000 description 3
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 239000012097 Lipofectamine 2000 Substances 0.000 description 3
- 108060001084 Luciferase Proteins 0.000 description 3
- 239000005089 Luciferase Substances 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 3
- 239000012124 Opti-MEM Substances 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 241000242739 Renilla Species 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
- 150000008064 anhydrides Chemical class 0.000 description 3
- METKIMKYRPQLGS-UHFFFAOYSA-N atenolol Chemical compound CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-UHFFFAOYSA-N 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 229960005156 digoxin Drugs 0.000 description 3
- MOAVUYWYFFCBNM-PUGKRICDSA-N digoxin(1-) Chemical compound C[C@H]([C@H]([C@H](C1)O)O)O[C@H]1O[C@H]([C@@H](C)O[C@H](C1)O[C@H]([C@@H](C)O[C@H](C2)O[C@@H](CC3)C[C@@H](CC4)[C@@]3(C)[C@@H](C[C@H]([C@]3(C)[C@H](CC5)C([CH-]O6)=CC6=O)O)[C@@H]4[C@]35O)[C@H]2O)[C@H]1O MOAVUYWYFFCBNM-PUGKRICDSA-N 0.000 description 3
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 150000007529 inorganic bases Chemical class 0.000 description 3
- 229940125425 inverse agonist Drugs 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 102000006255 nuclear receptors Human genes 0.000 description 3
- 108020004017 nuclear receptors Proteins 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- IPEHBUMCGVEMRF-UHFFFAOYSA-N pyrazinecarboxamide Chemical compound NC(=O)C1=CN=CC=N1 IPEHBUMCGVEMRF-UHFFFAOYSA-N 0.000 description 3
- 125000004076 pyridyl group Chemical group 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 239000012096 transfection reagent Substances 0.000 description 3
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 description 2
- OFNLCTNTFQJNAT-UHFFFAOYSA-N 1-ethyl-2-oxo-N-(2-oxo-2-pyrrolidin-1-ylethyl)benzo[cd]indole-6-sulfonamide Chemical compound C(C)N1C(C2=C3C(C(=CC=C13)S(=O)(=O)NCC(N1CCCC1)=O)=CC=C2)=O OFNLCTNTFQJNAT-UHFFFAOYSA-N 0.000 description 2
- GPYLCFQEKPUWLD-UHFFFAOYSA-N 1h-benzo[cd]indol-2-one Chemical compound C1=CC(C(=O)N2)=C3C2=CC=CC3=C1 GPYLCFQEKPUWLD-UHFFFAOYSA-N 0.000 description 2
- CNBCPSZIPVQUHA-UHFFFAOYSA-N 2-[(1-ethyl-2-oxobenzo[cd]indol-6-yl)sulfonylamino]benzoic acid Chemical compound C1=CC(=C23)N(CC)C(=O)C2=CC=CC3=C1S(=O)(=O)NC1=CC=CC=C1C(O)=O CNBCPSZIPVQUHA-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- XPDWGBQVDMORPB-UHFFFAOYSA-N Fluoroform Chemical compound FC(F)F XPDWGBQVDMORPB-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- JEYWNNAZDLFBFF-UHFFFAOYSA-N Nafoxidine Chemical compound C1CC2=CC(OC)=CC=C2C(C=2C=CC(OCCN3CCCC3)=CC=2)=C1C1=CC=CC=C1 JEYWNNAZDLFBFF-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 108091008773 RAR-related orphan receptors γ Proteins 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Natural products CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 125000005873 benzo[d]thiazolyl group Chemical group 0.000 description 2
- 229940049706 benzodiazepine Drugs 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 159000000007 calcium salts Chemical class 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 229940099112 cornstarch Drugs 0.000 description 2
- 125000004093 cyano group Chemical group *C#N 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000006274 endogenous ligand Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000002024 ethyl acetate extract Substances 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 238000007913 intrathecal administration Methods 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- TWBYWOBDOCUKOW-UHFFFAOYSA-N isonicotinic acid Chemical compound OC(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-N 0.000 description 2
- 125000005956 isoquinolyl group Chemical group 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- 125000000842 isoxazolyl group Chemical group 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 159000000003 magnesium salts Chemical class 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 229950002366 nafoxidine Drugs 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 125000002971 oxazolyl group Chemical group 0.000 description 2
- 239000003182 parenteral nutrition solution Substances 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 235000021003 saturated fats Nutrition 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 239000008279 sol Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 2
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 2
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 description 2
- 229940096998 ursolic acid Drugs 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- MMAIJMWMJMKEPE-UHFFFAOYSA-N (1,3-dioxophenalen-2-yl) 4-methylbenzenesulfonate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)OC(C1=O)C(=O)C2=C3C1=CC=CC3=CC=C2 MMAIJMWMJMKEPE-UHFFFAOYSA-N 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- UWYVPFMHMJIBHE-OWOJBTEDSA-N (e)-2-hydroxybut-2-enedioic acid Chemical compound OC(=O)\C=C(\O)C(O)=O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
- KEQGZUUPPQEDPF-UHFFFAOYSA-N 1,3-dichloro-5,5-dimethylimidazolidine-2,4-dione Chemical compound CC1(C)N(Cl)C(=O)N(Cl)C1=O KEQGZUUPPQEDPF-UHFFFAOYSA-N 0.000 description 1
- 125000006091 1,3-dioxolane group Chemical class 0.000 description 1
- XGIKILRODBEJIL-UHFFFAOYSA-N 1-(ethylamino)ethanol Chemical compound CCNC(C)O XGIKILRODBEJIL-UHFFFAOYSA-N 0.000 description 1
- QRVNUWSLHXSXMK-UHFFFAOYSA-N 1-[[(1-ethyl-2-oxobenzo[cd]indol-6-yl)sulfonylamino]methyl]cyclopentane-1-carboxylic acid Chemical compound CCN1C(=O)c2cccc3c(ccc1c23)S(=O)(=O)NCC1(CCCC1)C(O)=O QRVNUWSLHXSXMK-UHFFFAOYSA-N 0.000 description 1
- BYZKRKXJSNSHEE-UHFFFAOYSA-N 1-ethyl-2-benzo[cd]indolone Chemical compound C1=CC(N(CC)C2=O)=C3C2=CC=CC3=C1 BYZKRKXJSNSHEE-UHFFFAOYSA-N 0.000 description 1
- IIKQWKDJPZHRJE-UHFFFAOYSA-N 1-ethyl-2-oxo-N-(2-pyridinylmethyl)-6-benzo[cd]indolesulfonamide Chemical compound C1=CC(=C23)N(CC)C(=O)C2=CC=CC3=C1S(=O)(=O)NCC1=CC=CC=N1 IIKQWKDJPZHRJE-UHFFFAOYSA-N 0.000 description 1
- BCFMZQAGHBFDET-UHFFFAOYSA-N 1-ethyl-2-oxo-N-[(3,4,5-trifluorophenyl)methyl]benzo[cd]indole-6-sulfonamide Chemical compound C(C)N1C(C2=C3C(C(=CC=C13)S(=O)(=O)NCC1=CC(=C(C(=C1)F)F)F)=CC=C2)=O BCFMZQAGHBFDET-UHFFFAOYSA-N 0.000 description 1
- GCELTFSMFGNKQI-UHFFFAOYSA-N 1-ethyl-2-oxo-N-[(3-propan-2-yl-4,5-dihydro-1,2-oxazol-5-yl)methyl]benzo[cd]indole-6-sulfonamide Chemical compound C(C)N1C(C2=C3C(C(=CC=C13)S(=O)(=O)NCC1CC(=NO1)C(C)C)=CC=C2)=O GCELTFSMFGNKQI-UHFFFAOYSA-N 0.000 description 1
- BYPAKGDAQWDQLM-UHFFFAOYSA-N 1-ethyl-2-oxo-N-[[4-(trifluoromethyl)phenyl]methyl]benzo[cd]indole-6-sulfonamide Chemical compound C(C)N1C(C2=C3C(C(=CC=C13)S(=O)(=O)NCC1=CC=C(C=C1)C(F)(F)F)=CC=C2)=O BYPAKGDAQWDQLM-UHFFFAOYSA-N 0.000 description 1
- RIHWZRSLZORHBM-UHFFFAOYSA-N 1-ethyl-2-oxo-n-(3-phenylphenyl)benzo[cd]indole-6-sulfonamide Chemical compound C1=CC(=C23)N(CC)C(=O)C2=CC=CC3=C1S(=O)(=O)NC(C=1)=CC=CC=1C1=CC=CC=C1 RIHWZRSLZORHBM-UHFFFAOYSA-N 0.000 description 1
- YHNPFOVWPDMOEW-UHFFFAOYSA-N 1-ethyl-2-oxobenzo[cd]indole-6-sulfonyl chloride Chemical compound C1=CC(N(CC)C2=O)=C3C2=CC=CC3=C1S(Cl)(=O)=O YHNPFOVWPDMOEW-UHFFFAOYSA-N 0.000 description 1
- WLQWKZZDKDHLLN-UHFFFAOYSA-N 1-ethyl-6-[4-(pyridin-2-ylmethyl)piperazin-1-yl]sulfonylbenzo[cd]indol-2-one Chemical compound C(C)N1C(C2=C3C(C(=CC=C13)S(=O)(=O)N1CCN(CC1)CC1=NC=CC=C1)=CC=C2)=O WLQWKZZDKDHLLN-UHFFFAOYSA-N 0.000 description 1
- UCLROWGKLQFBAY-UHFFFAOYSA-N 1-ethyl-6-[4-(pyridin-4-ylmethyl)piperazin-1-yl]sulfonylbenzo[cd]indol-2-one Chemical compound C(C)N1C(C2=C3C(C(=CC=C13)S(=O)(=O)N1CCN(CC1)CC1=CC=NC=C1)=CC=C2)=O UCLROWGKLQFBAY-UHFFFAOYSA-N 0.000 description 1
- UVHFKRSIBZJWTD-UHFFFAOYSA-N 1-ethyl-N-(1-ethyl-2-oxobenzo[cd]indol-6-yl)sulfonyl-N-(5-fluoro-2-methylphenyl)-2-oxobenzo[cd]indole-6-sulfonamide Chemical compound C(C)N1C(C2=C3C(C(=CC=C13)S(=O)(=O)N(C1=C(C=CC(=C1)F)C)S(=O)(=O)C=1C=3C4=C(C(N(C4=CC=1)CC)=O)C=CC=3)=CC=C2)=O UVHFKRSIBZJWTD-UHFFFAOYSA-N 0.000 description 1
- OFPBMSSGXBNKHP-UHFFFAOYSA-N 1-ethyl-N-(2-ethylsulfonylethyl)-2-oxobenzo[cd]indole-6-sulfonamide Chemical compound C(C)N1C(C2=C3C(C(=CC=C13)S(=O)(=O)NCCS(=O)(=O)CC)=CC=C2)=O OFPBMSSGXBNKHP-UHFFFAOYSA-N 0.000 description 1
- PUCXXOXGVULFAP-UHFFFAOYSA-N 1-ethyl-N-(3-methyl-1-pyridin-3-ylbutyl)-2-oxobenzo[cd]indole-6-sulfonamide Chemical compound C(C)N1C(C2=C3C(C(=CC=C13)S(=O)(=O)NC(CC(C)C)C=1C=NC=CC=1)=CC=C2)=O PUCXXOXGVULFAP-UHFFFAOYSA-N 0.000 description 1
- RITCINXEOONILY-UHFFFAOYSA-N 1-ethyl-N-[(2-fluorophenyl)methyl]-2-oxobenzo[cd]indole-6-sulfonamide Chemical compound CCN1C(=O)c2cccc3c(ccc1c23)S(=O)(=O)NCc1ccccc1F RITCINXEOONILY-UHFFFAOYSA-N 0.000 description 1
- QUFOSUFJVBJBLG-UHFFFAOYSA-N 1-ethyl-N-[(2-methylphenyl)methyl]-2-oxobenzo[cd]indole-6-sulfonamide Chemical compound C(C)N1C(C2=C3C(C(=CC=C13)S(=O)(=O)NCC1=C(C=CC=C1)C)=CC=C2)=O QUFOSUFJVBJBLG-UHFFFAOYSA-N 0.000 description 1
- KFUPUVMAFVQHOT-UHFFFAOYSA-N 1-ethyl-N-[(3-fluoro-4-methylphenyl)methyl]-2-oxobenzo[cd]indole-6-sulfonamide Chemical compound C(C)N1C(C2=C3C(C(=CC=C13)S(=O)(=O)NCC1=CC(=C(C=C1)C)F)=CC=C2)=O KFUPUVMAFVQHOT-UHFFFAOYSA-N 0.000 description 1
- YWWKBODHMUQASX-UHFFFAOYSA-N 1-ethyl-N-[(3-methylphenyl)methyl]-2-oxobenzo[cd]indole-6-sulfonamide Chemical compound C(C)N1C(C2=C3C(C(=CC=C13)S(=O)(=O)NCC1=CC(=CC=C1)C)=CC=C2)=O YWWKBODHMUQASX-UHFFFAOYSA-N 0.000 description 1
- HBEIJBBCVOWKHQ-UHFFFAOYSA-N 1-ethyl-N-[(4-fluorophenyl)methyl]-2-oxobenzo[cd]indole-6-sulfonamide Chemical compound C(C)N1C(C2=C3C(C(=CC=C13)S(=O)(=O)NCC1=CC=C(C=C1)F)=CC=C2)=O HBEIJBBCVOWKHQ-UHFFFAOYSA-N 0.000 description 1
- NSLJOFXJVMOZGY-UHFFFAOYSA-N 1-ethyl-N-[(4-methylmorpholin-2-yl)methyl]-2-oxobenzo[cd]indole-6-sulfonamide Chemical compound C(C)N1C(C2=C3C(C(=CC=C13)S(=O)(=O)NCC1CN(CCO1)C)=CC=C2)=O NSLJOFXJVMOZGY-UHFFFAOYSA-N 0.000 description 1
- CHTKQKSSDOCRRB-UHFFFAOYSA-N 1-ethyl-N-[(4-methylphenyl)methyl]-2-oxobenzo[cd]indole-6-sulfonamide Chemical compound C(C)N1C(C2=C3C(C(=CC=C13)S(=O)(=O)NCC1=CC=C(C=C1)C)=CC=C2)=O CHTKQKSSDOCRRB-UHFFFAOYSA-N 0.000 description 1
- WAZATKBOLMGOEL-UHFFFAOYSA-N 1-ethyl-N-[2-(4-fluorophenyl)ethyl]-2-oxobenzo[cd]indole-6-sulfonamide Chemical compound C(C)N1C(C2=C3C(C(=CC=C13)S(=O)(=O)NCCC1=CC=C(C=C1)F)=CC=C2)=O WAZATKBOLMGOEL-UHFFFAOYSA-N 0.000 description 1
- MOSVYFYSQBDGJR-UHFFFAOYSA-N 1-ethyl-N-[3-(4-morpholinyl)propyl]-2-oxo-6-benzo[cd]indolesulfonamide Chemical compound C1=CC(=C23)N(CC)C(=O)C2=CC=CC3=C1S(=O)(=O)NCCCN1CCOCC1 MOSVYFYSQBDGJR-UHFFFAOYSA-N 0.000 description 1
- BQEJBPVZVKZEHL-UHFFFAOYSA-N 1-ethyl-N-[[4-fluoro-3-(trifluoromethyl)phenyl]methyl]-2-oxobenzo[cd]indole-6-sulfonamide Chemical compound C(C)N1C(C2=C3C(C(=CC=C13)S(=O)(=O)NCC1=CC(=C(C=C1)F)C(F)(F)F)=CC=C2)=O BQEJBPVZVKZEHL-UHFFFAOYSA-N 0.000 description 1
- YPMVZDYQGAKLGQ-UHFFFAOYSA-N 1-ethyl-N-isoquinolin-7-yl-2-oxobenzo[cd]indole-6-sulfonamide Chemical compound C(C)N1C(C2=C3C(C(=CC=C13)S(=O)(=O)NC1=CC=C3C=CN=CC3=C1)=CC=C2)=O YPMVZDYQGAKLGQ-UHFFFAOYSA-N 0.000 description 1
- DWAFHBUBFQTYQY-UHFFFAOYSA-N 1-ethyl-n-(2-morpholin-4-ylethyl)-2-oxobenzo[cd]indole-6-sulfonamide Chemical compound C1=CC(=C23)N(CC)C(=O)C2=CC=CC3=C1S(=O)(=O)NCCN1CCOCC1 DWAFHBUBFQTYQY-UHFFFAOYSA-N 0.000 description 1
- NAZKAVKQESNSNR-UHFFFAOYSA-N 1-ethyl-n-(3-methoxyphenyl)-2-oxobenzo[cd]indole-6-sulfonamide Chemical compound C1=CC(=C23)N(CC)C(=O)C2=CC=CC3=C1S(=O)(=O)NC1=CC=CC(OC)=C1 NAZKAVKQESNSNR-UHFFFAOYSA-N 0.000 description 1
- SUFMFRWLORNKTP-UHFFFAOYSA-N 1-ethyl-n-(4-fluorophenyl)-2-oxobenzo[cd]indole-6-sulfonamide Chemical compound C1=CC(=C23)N(CC)C(=O)C2=CC=CC3=C1S(=O)(=O)NC1=CC=C(F)C=C1 SUFMFRWLORNKTP-UHFFFAOYSA-N 0.000 description 1
- YCOXQYUSYKAHEG-UHFFFAOYSA-N 1-ethyl-n-(4-morpholin-4-ylphenyl)-2-oxobenzo[cd]indole-6-sulfonamide Chemical compound C1=CC(=C23)N(CC)C(=O)C2=CC=CC3=C1S(=O)(=O)NC(C=C1)=CC=C1N1CCOCC1 YCOXQYUSYKAHEG-UHFFFAOYSA-N 0.000 description 1
- ZAFDZZBLLWYWKW-UHFFFAOYSA-N 1-ethyl-n-[(4-methoxyphenyl)methyl]-2-oxobenzo[cd]indole-6-sulfonamide Chemical compound C1=CC(=C23)N(CC)C(=O)C2=CC=CC3=C1S(=O)(=O)NCC1=CC=C(OC)C=C1 ZAFDZZBLLWYWKW-UHFFFAOYSA-N 0.000 description 1
- SCLDISKZJONBTM-UHFFFAOYSA-N 1-ethyl-n-[(5-fluoro-1h-indol-2-yl)methyl]-2-oxobenzo[cd]indole-6-sulfonamide Chemical compound FC1=CC=C2NC(CNS(=O)(=O)C3=C4C=CC=C5C(=O)N(C(C=C3)=C54)CC)=CC2=C1 SCLDISKZJONBTM-UHFFFAOYSA-N 0.000 description 1
- XZLRBEJBFPODQF-UHFFFAOYSA-N 1-ethyl-n-[(5-methoxy-1h-indol-2-yl)methyl]-2-oxobenzo[cd]indole-6-sulfonamide Chemical compound COC1=CC=C2NC(CNS(=O)(=O)C3=C4C=CC=C5C(=O)N(C(C=C3)=C54)CC)=CC2=C1 XZLRBEJBFPODQF-UHFFFAOYSA-N 0.000 description 1
- FLEGYXZFZBOCSJ-UHFFFAOYSA-N 1-ethyl-n-[(5-methyl-2h-indazol-3-yl)methyl]-2-oxobenzo[cd]indole-6-sulfonamide Chemical compound C1=C(C)C=C2C(CNS(=O)(=O)C3=C4C=CC=C5C(=O)N(C(C=C3)=C54)CC)=NNC2=C1 FLEGYXZFZBOCSJ-UHFFFAOYSA-N 0.000 description 1
- LVBJVCATWRVLGO-UHFFFAOYSA-N 1-ethyl-n-[[1-methyl-5-(trifluoromethyl)benzimidazol-2-yl]methyl]-2-oxobenzo[cd]indole-6-sulfonamide Chemical compound FC(F)(F)C1=CC=C2N(C)C(CNS(=O)(=O)C3=C4C=CC=C5C(=O)N(C(C=C3)=C54)CC)=NC2=C1 LVBJVCATWRVLGO-UHFFFAOYSA-N 0.000 description 1
- GNUSAABXOXWQNT-UHFFFAOYSA-N 1-ethyl-n-[[4-methyl-6-(trifluoromethyl)pyrimidin-2-yl]methyl]-2-oxobenzo[cd]indole-6-sulfonamide Chemical compound C1=CC(=C23)N(CC)C(=O)C2=CC=CC3=C1S(=O)(=O)NCC1=NC(C)=CC(C(F)(F)F)=N1 GNUSAABXOXWQNT-UHFFFAOYSA-N 0.000 description 1
- WRWPPGUCZBJXKX-UHFFFAOYSA-N 1-fluoro-4-methylbenzene Chemical compound CC1=CC=C(F)C=C1 WRWPPGUCZBJXKX-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- WGSSQBRNCISLKY-UHFFFAOYSA-N 2-[(1-ethyl-2-oxobenzo[cd]indol-6-yl)sulfonylamino]-3-(furan-2-yl)propanoic acid Chemical compound C(C)N1C(C2=C3C(C(=CC=C13)S(=O)(=O)NC(C(=O)O)CC=1OC=CC=1)=CC=C2)=O WGSSQBRNCISLKY-UHFFFAOYSA-N 0.000 description 1
- NBEJNEYJRHATSF-UHFFFAOYSA-N 2-[[(1-ethyl-2-oxobenzo[cd]indol-6-yl)sulfonylamino]methyl]benzoic acid Chemical compound C(C)N1C(C2=C3C(C(=CC=C13)S(=O)(=O)NCC1=C(C(=O)O)C=CC=C1)=CC=C2)=O NBEJNEYJRHATSF-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- OKDGRDCXVWSXDC-UHFFFAOYSA-N 2-chloropyridine Chemical class ClC1=CC=CC=N1 OKDGRDCXVWSXDC-UHFFFAOYSA-N 0.000 description 1
- OATZWNYZMHFZHU-UHFFFAOYSA-N 2-ethyl-2-[[(1-ethyl-2-oxobenzo[cd]indol-6-yl)sulfonylamino]methyl]butanoic acid Chemical compound C(C)C(C(=O)O)(CC)CNS(=O)(=O)C=1C=2C3=C(C(N(C3=CC=1)CC)=O)C=CC=2 OATZWNYZMHFZHU-UHFFFAOYSA-N 0.000 description 1
- WLJVXDMOQOGPHL-PPJXEINESA-N 2-phenylacetic acid Chemical compound O[14C](=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-PPJXEINESA-N 0.000 description 1
- 125000005809 3,4,5-trimethoxyphenyl group Chemical group [H]C1=C(OC([H])([H])[H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 description 1
- RMTFNDVZYPHUEF-XZBKPIIZSA-N 3-O-methyl-D-glucose Chemical compound O=C[C@H](O)[C@@H](OC)[C@H](O)[C@H](O)CO RMTFNDVZYPHUEF-XZBKPIIZSA-N 0.000 description 1
- IGQSEUSWXCUCSY-UHFFFAOYSA-N 3-[(1-ethyl-2-oxobenzo[cd]indol-6-yl)sulfonylamino]-3-(5-methylfuran-2-yl)propanoic acid Chemical compound C(C)N1C(C2=C3C(C(=CC=C13)S(=O)(=O)NC(CC(=O)O)C=1OC(=CC=1)C)=CC=C2)=O IGQSEUSWXCUCSY-UHFFFAOYSA-N 0.000 description 1
- QAIQQAXISBNHPL-UHFFFAOYSA-N 3-[(1-ethyl-2-oxobenzo[cd]indol-6-yl)sulfonylamino]heptanoic acid Chemical compound C(C)N1C(C2=C3C(C(=CC=C13)S(=O)(=O)NC(CC(=O)O)CCCC)=CC=C2)=O QAIQQAXISBNHPL-UHFFFAOYSA-N 0.000 description 1
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 description 1
- BQVLDLQFZWVOEA-UHFFFAOYSA-N 4-(3,5-dimethylphenyl)-3-[(1-ethyl-2-oxobenzo[cd]indol-6-yl)sulfonylamino]butanoic acid Chemical compound CC=1C=C(C=C(C=1)C)CC(CC(=O)O)NS(=O)(=O)C=1C=2C3=C(C(N(C3=CC=1)CC)=O)C=CC=2 BQVLDLQFZWVOEA-UHFFFAOYSA-N 0.000 description 1
- HVBSAKJJOYLTQU-UHFFFAOYSA-N 4-aminobenzenesulfonic acid Chemical compound NC1=CC=C(S(O)(=O)=O)C=C1 HVBSAKJJOYLTQU-UHFFFAOYSA-N 0.000 description 1
- HVCNXQOWACZAFN-UHFFFAOYSA-N 4-ethylmorpholine Chemical compound CCN1CCOCC1 HVCNXQOWACZAFN-UHFFFAOYSA-N 0.000 description 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- ZWXIXHAKODDHHY-UHFFFAOYSA-N 4-methyl-6-(trifluoromethyl)pyrimidine Chemical class CC1=CC(C(F)(F)F)=NC=N1 ZWXIXHAKODDHHY-UHFFFAOYSA-N 0.000 description 1
- TWNLPJUZPPUEIW-UHFFFAOYSA-N 5-[[(1-ethyl-2-oxobenzo[cd]indol-6-yl)sulfonylamino]methyl]thiophene-2-carboxylic acid Chemical compound C(C)N1C(C2=C3C(C(=CC=C13)S(=O)(=O)NCC1=CC=C(S1)C(=O)O)=CC=C2)=O TWNLPJUZPPUEIW-UHFFFAOYSA-N 0.000 description 1
- MXDXAFAFEXUPIX-UHFFFAOYSA-N 6-[4-(2-chlorophenyl)piperazin-1-yl]sulfonyl-1-ethylbenzo[cd]indol-2-one Chemical compound ClC1=C(C=CC=C1)N1CCN(CC1)S(=O)(=O)C=1C=2C3=C(C(N(C3=CC=1)CC)=O)C=CC=2 MXDXAFAFEXUPIX-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 241001044369 Amphion Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- KURGRPNQBJPBJD-UHFFFAOYSA-N C(C)(=O)C1(CCCCC1)NS(=O)(=O)C=1C=2C3=C(C(N(C3=CC=1)CC)=O)C=CC=2 Chemical compound C(C)(=O)C1(CCCCC1)NS(=O)(=O)C=1C=2C3=C(C(N(C3=CC=1)CC)=O)C=CC=2 KURGRPNQBJPBJD-UHFFFAOYSA-N 0.000 description 1
- AADSJPKBOIGAAW-CYYJNZCTSA-N C1=CC(=C23)N(CC)C(=O)C2=CC=CC3=C1S(=O)(=O)NC(C=C1)=CC=C1\N=N\C1=CC=CC=C1 Chemical compound C1=CC(=C23)N(CC)C(=O)C2=CC=CC3=C1S(=O)(=O)NC(C=C1)=CC=C1\N=N\C1=CC=CC=C1 AADSJPKBOIGAAW-CYYJNZCTSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108090000079 Glucocorticoid Receptors Proteins 0.000 description 1
- 102100033417 Glucocorticoid receptor Human genes 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000007821 HATU Substances 0.000 description 1
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000007993 MOPS buffer Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000003926 Myelitis Diseases 0.000 description 1
- BGRBFBXCSBWJHJ-UHFFFAOYSA-N N-(1,3-benzodioxol-5-ylmethyl)-1-ethyl-2-oxobenzo[cd]indole-6-sulfonamide Chemical compound O1COC2=C1C=CC(=C2)CNS(=O)(=O)C=1C=2C3=C(C(N(C3=CC=1)CC)=O)C=CC=2 BGRBFBXCSBWJHJ-UHFFFAOYSA-N 0.000 description 1
- XVCAKXWYYQVMQC-UHFFFAOYSA-N N-(2,4-difluorophenyl)-1-ethyl-2-oxobenzo[cd]indole-6-sulfonamide Chemical compound FC1=C(C=CC(=C1)F)NS(=O)(=O)C=1C=2C3=C(C(N(C3=CC=1)CC)=O)C=CC=2 XVCAKXWYYQVMQC-UHFFFAOYSA-N 0.000 description 1
- LLUXHQYYAQRGKI-UHFFFAOYSA-N N-[(2-chloro-6-fluorophenyl)methyl]-1-ethyl-2-oxobenzo[cd]indole-6-sulfonamide Chemical compound ClC1=C(CNS(=O)(=O)C=2C=3C4=C(C(N(C4=CC=2)CC)=O)C=CC=3)C(=CC=C1)F LLUXHQYYAQRGKI-UHFFFAOYSA-N 0.000 description 1
- GDVVXKDWNBQOCY-UHFFFAOYSA-N N-[(3,5-dimethyl-4H-1,2-oxazol-5-yl)methyl]-1-ethyl-2-oxobenzo[cd]indole-6-sulfonamide Chemical compound CCN1C(=O)c2cccc3c(ccc1c23)S(=O)(=O)NCC1(C)CC(C)=NO1 GDVVXKDWNBQOCY-UHFFFAOYSA-N 0.000 description 1
- JMNOKWJDMLLHPS-UHFFFAOYSA-N N-[(4-bromo-2-fluorophenyl)methyl]-1-ethyl-2-oxobenzo[cd]indole-6-sulfonamide Chemical compound BrC1=CC(=C(CNS(=O)(=O)C=2C=3C4=C(C(N(C4=CC=2)CC)=O)C=CC=3)C=C1)F JMNOKWJDMLLHPS-UHFFFAOYSA-N 0.000 description 1
- ADDPCDZUTDTKNU-UHFFFAOYSA-N N-[(4-tert-butylphenyl)methyl]-1-ethyl-2-oxobenzo[cd]indole-6-sulfonamide Chemical compound C(C)(C)(C)C1=CC=C(CNS(=O)(=O)C=2C=3C4=C(C(N(C4=CC=2)CC)=O)C=CC=3)C=C1 ADDPCDZUTDTKNU-UHFFFAOYSA-N 0.000 description 1
- FWDBJJJADNLPSJ-UHFFFAOYSA-N N-[(6-chloropyridin-3-yl)methyl]-1-ethyl-2-oxobenzo[cd]indole-6-sulfonamide Chemical compound ClC1=CC=C(C=N1)CNS(=O)(=O)C=1C=2C3=C(C(N(C3=CC=1)CC)=O)C=CC=2 FWDBJJJADNLPSJ-UHFFFAOYSA-N 0.000 description 1
- JUTMNVBZSGSYGG-UHFFFAOYSA-N N-[2-(2-chlorophenyl)ethyl]-1-ethyl-2-oxobenzo[cd]indole-6-sulfonamide Chemical compound ClC1=C(CCNS(=O)(=O)C=2C=3C4=C(C(N(C4=CC=2)CC)=O)C=CC=3)C=CC=C1 JUTMNVBZSGSYGG-UHFFFAOYSA-N 0.000 description 1
- IXHXGPOFOGHOGX-UHFFFAOYSA-N N-[2-(3-chlorophenyl)ethyl]-1-ethyl-2-oxobenzo[cd]indole-6-sulfonamide Chemical compound ClC=1C=C(CCNS(=O)(=O)C=2C=3C4=C(C(N(C4=CC=2)CC)=O)C=CC=3)C=CC=1 IXHXGPOFOGHOGX-UHFFFAOYSA-N 0.000 description 1
- XVGYCKTYKPEPNJ-UHFFFAOYSA-N N-[2-(4-chlorophenyl)ethyl]-1-ethyl-2-oxobenzo[cd]indole-6-sulfonamide Chemical compound ClC1=CC=C(CCNS(=O)(=O)C=2C=3C4=C(C(N(C4=CC=2)CC)=O)C=CC=3)C=C1 XVGYCKTYKPEPNJ-UHFFFAOYSA-N 0.000 description 1
- AZXPDISIFJIKHJ-UHFFFAOYSA-N N-[3-bromo-5-(trifluoromethyl)phenyl]-1-ethyl-2-oxobenzo[cd]indole-6-sulfonamide Chemical compound BrC=1C=C(C=C(C=1)C(F)(F)F)NS(=O)(=O)C=1C=2C3=C(C(N(C3=CC=1)CC)=O)C=CC=2 AZXPDISIFJIKHJ-UHFFFAOYSA-N 0.000 description 1
- PWQHOZJOFCEBQC-UHFFFAOYSA-N N-[4-chloro-3-(trifluoromethyl)phenyl]-1-ethyl-2-oxobenzo[cd]indole-6-sulfonamide Chemical compound ClC1=C(C=C(C=C1)NS(=O)(=O)C=1C=2C3=C(C(N(C3=CC=1)CC)=O)C=CC=2)C(F)(F)F PWQHOZJOFCEBQC-UHFFFAOYSA-N 0.000 description 1
- FAALMMNBSWGUEJ-UHFFFAOYSA-N N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-ethyl-2-oxobenzo[cd]indole-6-sulfonamide Chemical compound FC(C=1C=C(CNS(=O)(=O)C=2C=3C4=C(C(N(C4=CC=2)CC)=O)C=CC=3)C=C(C=1)C(F)(F)F)(F)F FAALMMNBSWGUEJ-UHFFFAOYSA-N 0.000 description 1
- RSLYPFXUIIJUAK-UHFFFAOYSA-N N-benzhydryl-1-ethyl-2-oxobenzo[cd]indole-6-sulfonamide Chemical compound C1(=CC=CC=C1)C(NS(=O)(=O)C=1C=2C3=C(C(N(C3=CC=1)CC)=O)C=CC=2)C1=CC=CC=C1 RSLYPFXUIIJUAK-UHFFFAOYSA-N 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 102100023421 Nuclear receptor ROR-gamma Human genes 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229920003110 Primojel Polymers 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 239000008156 Ringer's lactate solution Substances 0.000 description 1
- OZBSSKGBKHOLGA-UHFFFAOYSA-N SR 1001 Chemical compound S1C(NC(=O)C)=NC(C)=C1S(=O)(=O)NC1=CC=C(C(O)(C(F)(F)F)C(F)(F)F)C=C1 OZBSSKGBKHOLGA-UHFFFAOYSA-N 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- ZEEBGORNQSEQBE-UHFFFAOYSA-N [2-(3-phenylphenoxy)-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound C1(=CC(=CC=C1)OC1=NC(=CC(=C1)CN)C(F)(F)F)C1=CC=CC=C1 ZEEBGORNQSEQBE-UHFFFAOYSA-N 0.000 description 1
- SAHIZENKTPRYSN-UHFFFAOYSA-N [2-[3-(phenoxymethyl)phenoxy]-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound O(C1=CC=CC=C1)CC=1C=C(OC2=NC(=CC(=C2)CN)C(F)(F)F)C=CC=1 SAHIZENKTPRYSN-UHFFFAOYSA-N 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 229920000180 alkyd Polymers 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 125000001118 alkylidene group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 238000003016 alphascreen Methods 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 159000000013 aluminium salts Chemical class 0.000 description 1
- 229910000329 aluminium sulfate Inorganic materials 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 230000003851 biochemical process Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- QNEFNFIKZWUAEQ-UHFFFAOYSA-N carbonic acid;potassium Chemical compound [K].OC(O)=O QNEFNFIKZWUAEQ-UHFFFAOYSA-N 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- XTHPWXDJESJLNJ-UHFFFAOYSA-N chlorosulfonic acid Substances OS(Cl)(=O)=O XTHPWXDJESJLNJ-UHFFFAOYSA-N 0.000 description 1
- 150000001841 cholesterols Chemical class 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000005595 deprotonation Effects 0.000 description 1
- 238000010537 deprotonation reaction Methods 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- FDPIMTJIUBPUKL-UHFFFAOYSA-N dimethylacetone Natural products CCC(=O)CC FDPIMTJIUBPUKL-UHFFFAOYSA-N 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- BXBSSGWGYRFAEK-UHFFFAOYSA-N ethyl 1-[[(1-ethyl-2-oxobenzo[cd]indol-6-yl)sulfonylamino]methyl]cyclopentane-1-carboxylate Chemical compound C(C)OC(=O)C1(CCCC1)CNS(=O)(=O)C=1C=2C3=C(C(N(C3=CC=1)CC)=O)C=CC=2 BXBSSGWGYRFAEK-UHFFFAOYSA-N 0.000 description 1
- PMMZFMFPBNVKBE-UHFFFAOYSA-N ethyl 2-[(1-ethyl-2-oxobenzo[cd]indol-6-yl)sulfonylamino]-3-(furan-2-yl)propanoate Chemical compound CCOC(=O)C(Cc1ccco1)NS(=O)(=O)c1ccc2N(CC)C(=O)c3cccc1c23 PMMZFMFPBNVKBE-UHFFFAOYSA-N 0.000 description 1
- DEBNNXJSFGNBMW-UHFFFAOYSA-N ethyl 2-[[(1-ethyl-2-oxobenzo[cd]indol-6-yl)sulfonylamino]methyl]benzoate Chemical compound CCOC(=O)c1ccccc1CNS(=O)(=O)c1ccc2N(CC)C(=O)c3cccc1c23 DEBNNXJSFGNBMW-UHFFFAOYSA-N 0.000 description 1
- RJYCJKKLHHBJJU-UHFFFAOYSA-N ethyl 3-[(1-ethyl-2-oxobenzo[cd]indol-6-yl)sulfonylamino]-3-(5-methylfuran-2-yl)propanoate Chemical compound CCOC(=O)CC(NS(=O)(=O)c1ccc2N(CC)C(=O)c3cccc1c23)c1ccc(C)o1 RJYCJKKLHHBJJU-UHFFFAOYSA-N 0.000 description 1
- OGBVCIBUNUBGAF-UHFFFAOYSA-N ethyl 4-(3,5-dimethylphenyl)-3-[(1-ethyl-2-oxobenzo[cd]indol-6-yl)sulfonylamino]butanoate Chemical compound CCOC(=O)CC(Cc1cc(C)cc(C)c1)NS(=O)(=O)c1ccc2N(CC)C(=O)c3cccc1c23 OGBVCIBUNUBGAF-UHFFFAOYSA-N 0.000 description 1
- UGGCDUDPDNFZOD-UHFFFAOYSA-N ethyl 5-[[(1-ethyl-2-oxobenzo[cd]indol-6-yl)sulfonylamino]methyl]thiophene-2-carboxylate Chemical compound CCOC(=O)c1ccc(CNS(=O)(=O)c2ccc3N(CC)C(=O)c4cccc2c34)s1 UGGCDUDPDNFZOD-UHFFFAOYSA-N 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- DQOCFCZRZOAIBN-WZHZPDAFSA-L hydroxycobalamin Chemical compound O.[Co+2].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O DQOCFCZRZOAIBN-WZHZPDAFSA-L 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 150000002505 iron Chemical class 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229940045996 isethionic acid Drugs 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 108020001756 ligand binding domains Proteins 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 102000004311 liver X receptors Human genes 0.000 description 1
- 108090000865 liver X receptors Proteins 0.000 description 1
- 238000009593 lumbar puncture Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 150000002696 manganese Chemical class 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229910000474 mercury oxide Inorganic materials 0.000 description 1
- UKWHYYKOEPRTIC-UHFFFAOYSA-N mercury(ii) oxide Chemical compound [Hg]=O UKWHYYKOEPRTIC-UHFFFAOYSA-N 0.000 description 1
- 229940100630 metacresol Drugs 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- IIHIJFJSXPDTNO-UHFFFAOYSA-N methyl cyclopentanecarboxylate Chemical class COC(=O)C1CCCC1 IIHIJFJSXPDTNO-UHFFFAOYSA-N 0.000 description 1
- 125000006431 methyl cyclopropyl group Chemical group 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- LNOPIUAQISRISI-UHFFFAOYSA-N n'-hydroxy-2-propan-2-ylsulfonylethanimidamide Chemical compound CC(C)S(=O)(=O)CC(N)=NO LNOPIUAQISRISI-UHFFFAOYSA-N 0.000 description 1
- ZEYXKTVEVPBQEM-UHFFFAOYSA-N n-(1-acetyl-2,3-dihydroindol-5-yl)-1-ethyl-2-oxobenzo[cd]indole-6-sulfonamide Chemical compound C1=C2N(C(C)=O)CCC2=CC(NS(=O)(=O)C2=C3C=CC=C4C(=O)N(C(C=C2)=C43)CC)=C1 ZEYXKTVEVPBQEM-UHFFFAOYSA-N 0.000 description 1
- OCAANUCNWHJWBD-UHFFFAOYSA-N n-(1-acetylpiperidin-4-yl)-1-ethyl-2-oxobenzo[cd]indole-6-sulfonamide Chemical compound C1=CC(=C23)N(CC)C(=O)C2=CC=CC3=C1S(=O)(=O)NC1CCN(C(C)=O)CC1 OCAANUCNWHJWBD-UHFFFAOYSA-N 0.000 description 1
- GIDFIRMLDHUPHY-UHFFFAOYSA-N n-(1-benzylpiperidin-4-yl)-1-ethyl-2-oxobenzo[cd]indole-6-sulfonamide Chemical compound C1=CC(=C23)N(CC)C(=O)C2=CC=CC3=C1S(=O)(=O)NC(CC1)CCN1CC1=CC=CC=C1 GIDFIRMLDHUPHY-UHFFFAOYSA-N 0.000 description 1
- DFBIMODMIYPVEE-UHFFFAOYSA-N n-(1-ethyl-2-oxobenzo[cd]indol-6-yl)sulfonyl-n-(4-methoxyphenyl)pyridine-4-carboxamide Chemical compound C1=CC(=C23)N(CC)C(=O)C2=CC=CC3=C1S(=O)(=O)N(C=1C=CC(OC)=CC=1)C(=O)C1=CC=NC=C1 DFBIMODMIYPVEE-UHFFFAOYSA-N 0.000 description 1
- QHDVAJSQYPJXAT-UHFFFAOYSA-N n-(2-acetylphenyl)-1-ethyl-2-oxobenzo[cd]indole-6-sulfonamide Chemical compound C1=CC(=C23)N(CC)C(=O)C2=CC=CC3=C1S(=O)(=O)NC1=CC=CC=C1C(C)=O QHDVAJSQYPJXAT-UHFFFAOYSA-N 0.000 description 1
- ISFQOKXXKVBMFZ-UHFFFAOYSA-N n-(2-benzoylphenyl)-1-ethyl-2-oxobenzo[cd]indole-6-sulfonamide Chemical compound C1=CC(=C23)N(CC)C(=O)C2=CC=CC3=C1S(=O)(=O)NC1=CC=CC=C1C(=O)C1=CC=CC=C1 ISFQOKXXKVBMFZ-UHFFFAOYSA-N 0.000 description 1
- JZFPQXYCIYFFCS-UHFFFAOYSA-N n-(2-tert-butylphenyl)-1-ethyl-2-oxobenzo[cd]indole-6-sulfonamide Chemical compound C1=CC(=C23)N(CC)C(=O)C2=CC=CC3=C1S(=O)(=O)NC1=CC=CC=C1C(C)(C)C JZFPQXYCIYFFCS-UHFFFAOYSA-N 0.000 description 1
- CSCNKXNQAPIIDE-UHFFFAOYSA-N n-(3,4-dimethoxyphenyl)-1-ethyl-2-oxobenzo[cd]indole-6-sulfonamide Chemical compound C1=CC(=C23)N(CC)C(=O)C2=CC=CC3=C1S(=O)(=O)NC1=CC=C(OC)C(OC)=C1 CSCNKXNQAPIIDE-UHFFFAOYSA-N 0.000 description 1
- GUQFBNIBOLNMAM-UHFFFAOYSA-N n-(3-acetylphenyl)-1-ethyl-2-oxobenzo[cd]indole-6-sulfonamide Chemical compound C1=CC(=C23)N(CC)C(=O)C2=CC=CC3=C1S(=O)(=O)NC1=CC=CC(C(C)=O)=C1 GUQFBNIBOLNMAM-UHFFFAOYSA-N 0.000 description 1
- FBJRRYCFCNCYHU-UHFFFAOYSA-N n-(3-tert-butylphenyl)-1-ethyl-2-oxobenzo[cd]indole-6-sulfonamide Chemical compound C1=CC(=C23)N(CC)C(=O)C2=CC=CC3=C1S(=O)(=O)NC1=CC=CC(C(C)(C)C)=C1 FBJRRYCFCNCYHU-UHFFFAOYSA-N 0.000 description 1
- TWOOVCPUMKWXNA-UHFFFAOYSA-N n-(4-acetylphenyl)-1-ethyl-2-oxobenzo[cd]indole-6-sulfonamide Chemical compound C1=CC(=C23)N(CC)C(=O)C2=CC=CC3=C1S(=O)(=O)NC1=CC=C(C(C)=O)C=C1 TWOOVCPUMKWXNA-UHFFFAOYSA-N 0.000 description 1
- DRBVUHJDRZINML-UHFFFAOYSA-N n-[(1-acetylpiperidin-4-yl)methyl]-1-ethyl-2-oxobenzo[cd]indole-6-sulfonamide Chemical compound C1=CC(=C23)N(CC)C(=O)C2=CC=CC3=C1S(=O)(=O)NCC1CCN(C(C)=O)CC1 DRBVUHJDRZINML-UHFFFAOYSA-N 0.000 description 1
- ZTUTWOVXSWGGSQ-UHFFFAOYSA-N n-[(2,5-dichlorophenyl)methyl]-1-ethyl-2-oxobenzo[cd]indole-6-sulfonamide Chemical compound C1=CC(=C23)N(CC)C(=O)C2=CC=CC3=C1S(=O)(=O)NCC1=CC(Cl)=CC=C1Cl ZTUTWOVXSWGGSQ-UHFFFAOYSA-N 0.000 description 1
- YFMAKAHUXUDKSK-UHFFFAOYSA-N n-[(2-chlorophenyl)methyl]-1-ethyl-2-oxobenzo[cd]indole-6-sulfonamide Chemical compound C1=CC(=C23)N(CC)C(=O)C2=CC=CC3=C1S(=O)(=O)NCC1=CC=CC=C1Cl YFMAKAHUXUDKSK-UHFFFAOYSA-N 0.000 description 1
- SXKUBJSGXSLHDC-UHFFFAOYSA-N n-[(3-chloro-4-fluorophenyl)methyl]-1-ethyl-2-oxobenzo[cd]indole-6-sulfonamide Chemical compound C1=CC(=C23)N(CC)C(=O)C2=CC=CC3=C1S(=O)(=O)NCC1=CC=C(F)C(Cl)=C1 SXKUBJSGXSLHDC-UHFFFAOYSA-N 0.000 description 1
- HQYQJCSODDOMTE-UHFFFAOYSA-N n-[4-[(1-ethyl-2-oxobenzo[cd]indol-6-yl)sulfonylamino]phenyl]acetamide Chemical compound C1=CC(=C23)N(CC)C(=O)C2=CC=CC3=C1S(=O)(=O)NC1=CC=C(NC(C)=O)C=C1 HQYQJCSODDOMTE-UHFFFAOYSA-N 0.000 description 1
- FOUVRVROXNFCJM-UHFFFAOYSA-N n-cyclopentyl-1-ethyl-2-oxobenzo[cd]indole-6-sulfonamide Chemical compound C1=CC(=C23)N(CC)C(=O)C2=CC=CC3=C1S(=O)(=O)NC1CCCC1 FOUVRVROXNFCJM-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- PVWOIHVRPOBWPI-UHFFFAOYSA-N n-propyl iodide Chemical compound CCCI PVWOIHVRPOBWPI-UHFFFAOYSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- DNUTZBZXLPWRJG-UHFFFAOYSA-M piperidine-1-carboxylate Chemical compound [O-]C(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-M 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920001084 poly(chloroprene) Polymers 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 229920001721 polyimide Polymers 0.000 description 1
- 239000009719 polyimide resin Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 229960005206 pyrazinamide Drugs 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 150000003222 pyridines Chemical class 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229960002668 sodium chloride Drugs 0.000 description 1
- 239000008354 sodium chloride injection Substances 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 229960005137 succinic acid Drugs 0.000 description 1
- 229950000244 sulfanilic acid Drugs 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- OSEKJLPRHACLQL-UHFFFAOYSA-N tert-butyl n-[3-[(1-ethyl-2-oxobenzo[cd]indol-6-yl)sulfonylamino]phenyl]carbamate Chemical compound C1=CC(=C23)N(CC)C(=O)C2=CC=CC3=C1S(=O)(=O)NC1=CC=CC(NC(=O)OC(C)(C)C)=C1 OSEKJLPRHACLQL-UHFFFAOYSA-N 0.000 description 1
- XBXCNNQPRYLIDE-UHFFFAOYSA-N tert-butylcarbamic acid Chemical compound CC(C)(C)NC(O)=O XBXCNNQPRYLIDE-UHFFFAOYSA-N 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 229960004559 theobromine Drugs 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/90—Benzo [c, d] indoles; Hydrogenated benzo [c, d] indoles
- C07D209/92—Naphthostyrils
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410821535.5A CN104530014B (zh) | 2013-12-25 | 2014-12-24 | 2‑氧代‑1,2‑二氢苯并[cd]吲哚‑6‑磺酰胺类化合物及其组合物和应用 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310729561 | 2013-12-25 | ||
CN2013107295610 | 2013-12-25 | ||
CN201410821535.5A CN104530014B (zh) | 2013-12-25 | 2014-12-24 | 2‑氧代‑1,2‑二氢苯并[cd]吲哚‑6‑磺酰胺类化合物及其组合物和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104530014A CN104530014A (zh) | 2015-04-22 |
CN104530014B true CN104530014B (zh) | 2018-03-20 |
Family
ID=52845685
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410821535.5A Active CN104530014B (zh) | 2013-12-25 | 2014-12-24 | 2‑氧代‑1,2‑二氢苯并[cd]吲哚‑6‑磺酰胺类化合物及其组合物和应用 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN104530014B (fr) |
WO (1) | WO2015096771A1 (fr) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111662226B (zh) * | 2015-01-28 | 2022-03-18 | 中国科学院广州生物医药与健康研究院 | 一种2-氧代-1,2-二氢苯并[cd]吲哚类化合物 |
CN107614062A (zh) | 2015-03-12 | 2018-01-19 | 加利福尼亚大学董事会 | 用RORγ抑制剂治疗癌症的方法 |
CN114790169A (zh) * | 2016-01-29 | 2022-07-26 | 中国科学院广州生物医药与健康研究院 | 四氢喹啉相关二环类化合物及其应用 |
WO2021047406A1 (fr) * | 2019-09-10 | 2021-03-18 | 四川科伦博泰生物医药股份有限公司 | Composé tricyclique, composition pharmaceutique le contenant, procédé de préparation correspondant et utilisation associée |
CN113912563A (zh) * | 2020-07-10 | 2022-01-11 | 中国科学院广州生物医药与健康研究院 | 一种苯并五元氮杂环化合物及其应用 |
CN111995563A (zh) * | 2020-08-04 | 2020-11-27 | 常州大学 | 磷酸二酯酶pde2活性抑制剂 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2606716A1 (de) * | 1975-02-21 | 1976-09-02 | Ciba Geigy Ag | Neue dispersionsfarbstoffe |
CN1863785A (zh) * | 2003-08-08 | 2006-11-15 | 沃泰克斯药物股份有限公司 | 在疼痛的治疗中用作钠或钙通道阻断剂的杂芳基氨基磺酰基苯基衍生物 |
WO2009016081A2 (fr) * | 2007-08-02 | 2009-02-05 | Actar Ab | Composés destinés à être utilisés en thérapie |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2487159A1 (fr) * | 2011-02-11 | 2012-08-15 | MSD Oss B.V. | Inhibiteurs du RORgammaT |
GB201207406D0 (en) * | 2012-04-27 | 2012-06-13 | Glaxo Group Ltd | Novel compounds |
UY34765A (es) * | 2012-04-27 | 2013-11-29 | Glaxo Group Ltd | Compuestos novedosos. |
-
2014
- 2014-12-24 CN CN201410821535.5A patent/CN104530014B/zh active Active
- 2014-12-25 WO PCT/CN2014/094942 patent/WO2015096771A1/fr active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2606716A1 (de) * | 1975-02-21 | 1976-09-02 | Ciba Geigy Ag | Neue dispersionsfarbstoffe |
CN1863785A (zh) * | 2003-08-08 | 2006-11-15 | 沃泰克斯药物股份有限公司 | 在疼痛的治疗中用作钠或钙通道阻断剂的杂芳基氨基磺酰基苯基衍生物 |
WO2009016081A2 (fr) * | 2007-08-02 | 2009-02-05 | Actar Ab | Composés destinés à être utilisés en thérapie |
Non-Patent Citations (5)
Title |
---|
CAS RN:438488-85-8、438488-77-8、438479-43-7、438489-03-3;CAS;《STN Registry》;20020712 * |
CAS RN:62104-12-5、62155-54-8、62104-14-7;CAS;《STN Registry》;19841116 * |
Identification and Characterization of Novel Inhibitors of mPTPB, an Essential Virulent Phosphatase from Mycobacterium tuberculosis;Lan Chen et al.;《Medicinal Chemistry Letters》;20100707;第7卷(第1期);355-359 * |
Identification of Novel Compounds That Increase SMN Protein Levels Using an Improved SMN2 Reporter Cell Assay;Jonathan J. Cherrry et al.;《Journal of Biomolecular Screening》;20120430;第17卷(第4期);481-495 * |
Virtual screening, selection and development of a benzindolone structural scaffold for inhibition of lumazine synthase;Arindam Talukdar et al.;《Bioorganic & Medicinal Chemistry》;20100408;第18卷(第10期);3518-3534 * |
Also Published As
Publication number | Publication date |
---|---|
WO2015096771A1 (fr) | 2015-07-02 |
CN104530014A (zh) | 2015-04-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104530014B (zh) | 2‑氧代‑1,2‑二氢苯并[cd]吲哚‑6‑磺酰胺类化合物及其组合物和应用 | |
DE60203263T2 (de) | Pyrazolderivate gegen tgf überexprimierung | |
CN105272904B (zh) | N-苯基酰胺类化合物及其应用 | |
US20030096737A1 (en) | Caspase inhibitors and uses thereof | |
CA3057886A1 (fr) | Inhibiteurs de bcl-2 comme agents d'induction de l'apoptose | |
RU2382029C2 (ru) | Новые производные циклогексана | |
BR112015027114B1 (pt) | Compostos inibidores seletivos de histona desacetilase e seu uso | |
WO2013134298A1 (fr) | Composés inhibiteurs de raf | |
CN103561576A (zh) | 脂质合成的杂环调节剂 | |
CN107669669A (zh) | 新颖的胰高血糖素受体拮抗剂 | |
CN102816130B (zh) | 噻唑化合物及其用途 | |
TWI748996B (zh) | 嘧啶類七元環化合物、其製備方法、藥用組合物及其應用 | |
TW201522306A (zh) | 雜環衍生物及其用途 | |
PT2238110E (pt) | Derivados de 5,6-bisaril-2-piridina-carboxamida, sua preparação e sua aplicação em terapia como antagonistas dos receptores da urotensina ii | |
ES2782357T3 (es) | Inhibidores de IRE 1 alfa | |
TW200924758A (en) | Therapeutic agents | |
JP2010535165A (ja) | mGlu5拮抗薬としての新規複素環系化合物 | |
KR101732989B1 (ko) | 1형 11-베타-하이드록시스테로이드 데하이드로게나제의 저해 화합물 | |
Jae et al. | Pyrrolidine-3-carboxylic acids as endothelin antagonists. 2. Sulfonamide-based ETA/ETB mixed antagonists | |
CN105968095B (zh) | 吲哚芳砜类衍生物及其制备方法与应用 | |
JP2011519966A (ja) | 新規なn−(2−アミノ−フェニル)−アクリルアミド | |
DE60311861T2 (de) | Pyrazolochinoline mit immunmodulierender wirkung | |
CN103951649B (zh) | 杂环取代异羟肟酸类芳香酰胺化合物或其药学上可接受的盐、及其制备方法和应用 | |
CN114634500B (zh) | 一种ptp1b抑制剂及其合成方法和用途 | |
DE69402004T2 (de) | Beta-mercapto-propanamidderivate verwendbar zur Behandlung kardiovaskularer Krankheiten oder Erkrankungen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |